[Serum levels of soluble intercellular adhesion molecule 1 in malignant lymphoproliferative disorders].
OBJECTIVE
To investigate the correlation of serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) with clinical situation and treatment outcome in lymphoproliferative disorders.


METHODS
Serum sICAM-1 levels were measured by immunoenzymatic assay.


RESULTS
Pre-treatment serum sICAM-1 levels were above normal in 41% (9/22) of multiple myeloma (MM), 53% (17/32) of non-Hodgkin's lymphoma (NHL) and 63% (12/19) of acute lymphocytic leukemia (ALL) patients. Serum sICAM-1 levels in MM were positively correlated with Bataille stages, but were not related to Durie stage. Meanwhile, sICAM-1 levels in NHL were associated with the category of pathology, Ann Arbor stage and B symptom, but were not related to serum LDH levels. sICAM-1 levels were significantly higher in ALL patients complicated with central nervous system leukemia (CNSL) than in those without CNSL. Patients with elevated serum sICAM-1 levels had poorer treatment outcomes. Serum sICAM-1 levels were returned to normal at remission.


CONCLUSIONS
Measurement of serum sICAM-1 levels in lymphoproliferative disorders patients is helpful for judging the clinical status and treatment outcome.
Li
D
D
Department of Hematology, Affiliated Hospital of Weifang Medical College, Weifang 261031.
Li
G
G
Cui
W
W
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood*
D018799:Intercellular Adhesion Molecule-1